PMID- 35264308
OWN - NLM
STAT- MEDLINE
DCOM- 20220615
LR  - 20220630
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 49
IP  - 2
DP  - 2022 Apr
TI  - Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing 
      their ability to cause acute kidney injury and informing their proper use.
PG  - 141-147
LID - S0093-7754(22)00012-4 [pii]
LID - 10.1053/j.seminoncol.2022.01.012 [doi]
AB  - Immune check point inhibitors (ICI) have secured regulatory approvals across the 
      world for the treatment of various types of cancers. Though not as frequent as 
      immune-related adverse events (AEs) involving other organs, a considerable number 
      of ICI-related renal AE have also been reported and predicting such events has 
      become important. We provide an updated review on possible mechanisms of 
      ICI-related acute kidney injury (AKI), related risk factors, and the use of ICIs 
      in patients with chronic kidney diseases (CKD). A systematic search for related 
      articles was conducted. Acute tubulointerstitial nephritis (ATIN) is known to be 
      the main cause of ICI-related AKI, with glomerulonephritis also a significant 
      cause. Factors including use of concurrent medications, extra-renal immune 
      related AEs, and combination of two or more immunotherapy drugs are possible risk 
      factors. Use of ICI in patients with CKD may be related to increased occurrence 
      of overall immune related AEs. If the diagnosis of ICI related renal AEs is 
      confirmed, prompt use of steroids is recommended, and in severe cases of AKI, 
      discontinuation of ICI should be considered.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Min, Ji Won
AU  - Min JW
AD  - Division of Nephrology, Department of Internal Medicine, Bucheon St. Mary's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, South 
      Korea.
FAU - Lim, Jeong Uk
AU  - Lim JU
AD  - Division of Pulmonary, Critical Care and Allergy, Department of Internal 
      Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic 
      University of Korea, Seoul, Republic of Korea. Electronic address: 
      cracovian@catholic.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220215
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - *Acute Kidney Injury/chemically induced/diagnosis/drug therapy
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Neoplasms/drug therapy
MH  - *Nephritis, Interstitial/chemically induced/diagnosis/drug therapy
MH  - *Renal Insufficiency, Chronic/chemically induced/drug therapy
OTO - NOTNLM
OT  - Acute kidney injury
OT  - Acute tubulointerstitial nephritis
OT  - Immune checkpoint inhibitor
OT  - Kidney
OT  - Renal
COIS- Declaration of Competing Interest The authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2022/03/11 06:00
MHDA- 2022/06/16 06:00
CRDT- 2022/03/10 05:34
PHST- 2021/07/20 00:00 [received]
PHST- 2021/09/27 00:00 [revised]
PHST- 2022/01/28 00:00 [accepted]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/06/16 06:00 [medline]
PHST- 2022/03/10 05:34 [entrez]
AID - S0093-7754(22)00012-4 [pii]
AID - 10.1053/j.seminoncol.2022.01.012 [doi]
PST - ppublish
SO  - Semin Oncol. 2022 Apr;49(2):141-147. doi: 10.1053/j.seminoncol.2022.01.012. Epub 
      2022 Feb 15.